Organon & Co. (NYSE:OGN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Organon & Co. (NYSE:OGN) have been given a consensus rating of “Hold” by the seven ratings firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $20.80.

Several research analysts have commented on OGN shares. Morgan Stanley reduced their price objective on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a report on Friday, February 14th. Barclays cut their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 14th. Finally, TD Cowen raised shares of Organon & Co. to a “hold” rating in a research note on Wednesday, January 15th.

Hedge Funds Weigh In On Organon & Co.

A number of large investors have recently added to or reduced their stakes in OGN. Sippican Capital Advisors grew its position in shares of Organon & Co. by 4.3% in the 3rd quarter. Sippican Capital Advisors now owns 15,230 shares of the company’s stock worth $291,000 after buying an additional 627 shares during the last quarter. Commerce Bank boosted its stake in Organon & Co. by 5.5% in the third quarter. Commerce Bank now owns 12,168 shares of the company’s stock valued at $233,000 after acquiring an additional 637 shares in the last quarter. MassMutual Private Wealth & Trust FSB grew its holdings in Organon & Co. by 32.4% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 2,749 shares of the company’s stock worth $41,000 after purchasing an additional 672 shares during the last quarter. Treasurer of the State of North Carolina grew its holdings in Organon & Co. by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 113,120 shares of the company’s stock worth $1,688,000 after purchasing an additional 710 shares during the last quarter. Finally, Beam Wealth Advisors Inc. increased its position in shares of Organon & Co. by 3.9% during the fourth quarter. Beam Wealth Advisors Inc. now owns 18,888 shares of the company’s stock worth $282,000 after purchasing an additional 717 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Trading Up 2.6 %

NYSE OGN opened at $15.69 on Friday. The stock has a market cap of $4.04 billion, a PE ratio of 4.71, a PEG ratio of 0.86 and a beta of 0.76. Organon & Co. has a 12 month low of $13.87 and a 12 month high of $23.10. The company’s 50-day moving average price is $15.36 and its 200-day moving average price is $17.31. The company has a current ratio of 1.70, a quick ratio of 1.21 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN) last released its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). Organon & Co. had a net margin of 13.49% and a return on equity of 431.62%. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.57 billion. Equities research analysts forecast that Organon & Co. will post 3.78 earnings per share for the current year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 13th. Investors of record on Monday, February 24th will be paid a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.14%. The ex-dividend date is Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.